Inspire Investing LLC Purchases 7,331 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Inspire Investing LLC grew its position in Exelixis, Inc. (NASDAQ:EXEL) by 25.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,659 shares of the biotechnology company’s stock after acquiring an additional 7,331 shares during the quarter. Inspire Investing LLC’s holdings in Exelixis were worth $1,221,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Hsbc Holdings PLC raised its stake in shares of Exelixis by 45.3% in the second quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock valued at $2,031,000 after purchasing an additional 28,126 shares in the last quarter. Seizert Capital Partners LLC raised its stake in shares of Exelixis by 8.0% in the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after buying an additional 34,875 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after buying an additional 991,494 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Exelixis by 60.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after acquiring an additional 20,641 shares during the period. Finally, Tri Ri Asset Management Corp acquired a new stake in shares of Exelixis during the 3rd quarter valued at about $4,396,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on EXEL. Truist Financial increased their price target on shares of Exelixis from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. Oppenheimer increased their target price on Exelixis from $38.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, January 16th. HC Wainwright boosted their price target on Exelixis from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, January 10th. JMP Securities reiterated a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research note on Thursday. Finally, TD Cowen boosted their target price on shares of Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus target price of $35.50.

Exelixis Price Performance

Shares of Exelixis stock opened at $34.13 on Friday. The firm has a 50 day simple moving average of $34.91 and a 200 day simple moving average of $29.64. Exelixis, Inc. has a fifty-two week low of $20.01 and a fifty-two week high of $37.59. The firm has a market cap of $9.75 billion, a P/E ratio of 21.88, a P/E/G ratio of 0.80 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. During the same period last year, the firm earned $0.10 EPS. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. On average, sell-side analysts expect that Exelixis, Inc. will post 1.74 EPS for the current year.

Insiders Place Their Bets

In related news, Director George Poste sold 30,000 shares of Exelixis stock in a transaction on Friday, November 1st. The stock was sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the completion of the sale, the director now directly owns 169,020 shares of the company’s stock, valued at $5,746,680. The trade was a 15.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Dana Aftab sold 1,162 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares in the company, valued at $15,666,873. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 314,736 shares of company stock valued at $10,849,110. 2.85% of the stock is currently owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.